Statera Biopharma, Inc. (STAB) DCF Valuation

Valoración de DCF de STATERA BIOPHARMA, Inc. (STAB)

US | Healthcare | Biotechnology | NASDAQ
Statera Biopharma, Inc. (STAB) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Statera Biopharma, Inc. (STAB) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Simplifique la valoración de Statera BioPharma, Inc. (STAB) con esta calculadora DCF personalizable! Con el Real Statera Biopharma, Inc. (STAB) Financials y las entradas de pronóstico ajustable, puede probar escenarios y descubrir el valor razonable de Statera BioPharma, Inc. (STAB) en minutos.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2017		 AY2
2018		 AY3
2019		 AY4
2020		 AY5
2021		 FY1
2022		 FY2
2023		 FY3
2024		 FY4
2025		 FY5
2026
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -5.6 -4.8 -2.4 -2.6 38.9 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .0 .0 .0 .0 .3 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -5.6 -4.8 -2.4 -2.6 38.7 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 8.8 4.1 .0 .6 2.0 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .6 .3 .0 .3 .3
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 -.4 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .2 .1 2.4 1.1 4.0 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 -.2 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % -71.2 -71.2 -71.2 -71.2 -71.2 -71.2 -71.2 -71.2 -71.2 -71.2
EBITAT -5.6 -4.8 -2.5 -2.8 66.2 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -6.0 -4.6 .5 -4.9 69.1 -3.6 .0 .0 .0 .0
WACC, % 4.72 4.72 4.72 4.72 4.72 4.72 4.72 4.72 4.72 4.72
PV UFCF
SUM PV UFCF -3.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -3
Net Debt 14
Equity Value -18
Diluted Shares Outstanding, MM 35
Equity Value Per Share -0.51

What You Will Get

  • Real STAB Financial Data: Pre-filled with Statera Biopharma’s historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Statera Biopharma’s intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive DCF Model: Features detailed unlevered and levered DCF valuation frameworks tailored for Statera Biopharma, Inc. (STAB).
  • WACC Calculation Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
  • Customizable Forecast Inputs: Easily modify growth projections, capital expenditures, and discount rates specific to Statera Biopharma, Inc. (STAB).
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Statera Biopharma, Inc. (STAB).
  • Interactive Dashboard and Visuals: Graphical representations that summarize essential valuation metrics for straightforward analysis.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Statera Biopharma, Inc.'s (STAB) preloaded data.
  • 2. Modify Assumptions: Adjust essential inputs such as growth rates, WACC, and capital expenditures.
  • 3. Analyze Results Instantly: The DCF model automatically calculates intrinsic value and NPV.
  • 4. Explore Scenarios: Evaluate various forecasts to assess different valuation results.
  • 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making process.

Why Choose This Calculator for Statera Biopharma, Inc. (STAB)?

  • User-Friendly Interface: Tailored for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters easily to suit your financial analysis.
  • Real-Time Valuation: Observe immediate updates to Statera's valuation with input modifications.
  • Preloaded Data: Comes with Statera’s actual financial metrics for swift assessments.
  • Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.

Who Should Use This Product?

  • Investors: Accurately assess Statera Biopharma, Inc.'s (STAB) fair value prior to making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Statera Biopharma, Inc. (STAB).
  • Consultants: Efficiently customize the template for valuation reports tailored to clients interested in Statera Biopharma, Inc. (STAB).
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like Statera Biopharma, Inc. (STAB).
  • Educators: Implement it as a teaching resource to illustrate valuation techniques relevant to Statera Biopharma, Inc. (STAB).

What the Template Contains

  • Pre-Filled DCF Model: Statera Biopharma’s financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Statera Biopharma’s profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.